STOP AF First Post-Approval Study to Evaluate Safety and Effectiveness of Arctic Front Cardiac Cryoablation Catheter in Treating Paroxysmal Atrial Fibrillation

What this Trial Is About

Researchers are conducting the STOP AF First Post-Approval Study, a prospective, global, multi-center observational trial focusing on patients with recurrent symptomatic paroxysmal atrial fibrillation AF. The study aims to collect long-term clinical performance and safety data on the Arctic Front Cardiac Cryoablation Catheter System as an alternative initial rhythm control strategy to antiarrhythmic drug therapy. This study is part of a post-approval condition required by the U.S. Food and Drug Administration. Participants undergo pulmonary vein isolation PVI using the Arctic Front cardiac cryoablation catheter system. The study observes patients treated with this device rather than assigning specific interventions, as it follows routine clinical care. The trial extends over several years to monitor outcomes and safety of this treatment approach in a real-world setting. During the study, participants are monitored for freedom from atrial fibrillation, atrial flutter, and atrial tachycardia over 36 months, as well as safety events for up to 12 months. Data collection includes tracking clinical outcomes and adverse events related to the cryoablation procedure. Participants will be observed according to standard care and study requirements, with follow-up assessments scheduled to gather these long-term results.

STOP AF First Post-Approval Study